ArticleCureus2026
Statin-Associated Immune-Mediated Necrotizing Myopathy Presenting as Persistent Hypertransaminasemia.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-mediated necrotizing myopathy is an uncommon autoimmune muscle disease that can be triggered by statin exposure and is often associated with antibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR). Typical presentations include subacute, symmetric proximal weakness with marked elevation of muscle enzymes, but some patients come to medical attention only because of abnormal laboratory tests, which can delay recognition. We report a middle-aged man with dyslipidemia and chronic hepatitis B virus infection who was referred for persistent elevation of aminotransferases on routine follow-up. Despite minimal muscle complaints, evaluation revealed marked hyperCKemia, strongly positive anti-HMGCR antibodies, and a muscle biopsy consistent with pauci-inflammatory necrotizing myopathy. Statins were discontinued, and combined glucocorticoid-methotrexate therapy led to progressive clinical improvement and complete biochemical remission. This case underscores the importance of considering an underlying myopathy in patients with otherwise unexplained hypertransaminasemia, particularly in the setting of statin exposure and coexisting liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.